Research Assistant Professor Travis C. Jackson, PhD, was awarded a five-year R01 grant from the National Institute of Neurological Disorders and Stroke. Dr. Jackson and his colleagues will investigate the therapeutic potential of a new neuroprotective approach that is aimed at improving neurological outcomes following a traumatic brain injury (TBI). In vitro and in vivo pre-clinical TBI models will be used to test the hypothesis that inhibiting the splicing factor RNA binding motif 5 (RBM5) decreases markers of axonal and cellular damage in injured CNS cells. Gene mutation experiments will determine which regions within the RBM5 protein will mediate the activation of downstream cell death pathways. These results will define which functional domains hold the greatest promise for TBI therapeutic targeting using future small-molecule inhibitors. This project represents the most comprehensive study to date germane to elucidating the role of RBM5 signaling in the brain.